
FDA Approves Keytruda Combination for Advanced Endometrial Cancer
WASHINGTON, D.C. — On Monday, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with primary …
FDA Approves Keytruda Combination for Advanced Endometrial Cancer Read More